Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
ResMed (RMD) filed a Form 144 proposing the sale of 100 shares of common stock through Fidelity Brokerage Services with an approximate market value of $27,436, scheduled for 10/01/2025. The shares were acquired by restricted stock vesting on 11/11/2023 and were granted as compensation. The filer previously sold 66 shares on 07/01/2025 for $16,961.34 and 50 shares on 08/01/2025 for $14,095.00. The filing includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.
Form 144 notice for ResMed Inc. (RMD) shows proposed sales of common stock by an individual affiliated with the issuer. The filing lists a broker (Fidelity Brokerage Services) and an intended sale of 3,000 shares with an aggregate market value of $823,080 to be sold on 10/01/2025 on the NYSE. The filer acquired 1,000 shares on 11/11/2022 by restricted stock vesting (compensation) and 2,000 shares on 10/01/2025 via option exercise (options granted 11/14/2018) with cash payment. The form also discloses sales by the same person totaling 9,883 shares in the prior three months with gross proceeds reported for each sale.
Michael J. Farrell, Chief Executive Officer of ResMed Inc. (RMD), reported transactions on Form 4 relating to common stock and stock options. On 09/08/2025 he acquired 8,009 shares at $101.64 per share under a Rule 10b5-1 plan adopted October 31, 2024, and sold 8,009 shares in multiple trades at a weighted-average price of $278.1359 (trade prices ranged $275.27–$279.57). Following the reported transactions his direct beneficial ownership is reported as 475,801 shares after the purchase and 467,792 shares after the sale, with an additional 2,090 shares held indirectly via the Lisette and Michael Farrell Family Trust. He also reports holding 16,020 options exercisable through 11/14/2025; options vest one-third per year.
ResMed Inc. (RMD) Form 144 reports a proposed sale of 8,009 common shares through Fidelity Brokerage Services with an aggregate market value of $2,227,590.84. The filing lists approximately 146,414,839 shares outstanding and an intended sale date of 09/08/2025 on the NYSE.
The shares were acquired under an option granted on 11/14/2018 and shown as acquired on 09/08/2025, with payment in cash. The filer previously sold 8,009 shares on 06/09/2025, 07/07/2025 and 08/07/2025 with gross proceeds of $2,011,909.65, $2,056,076.09 and $2,238,378.55, respectively.
ResMed Inc. (RMD) Form 4: Director Nicole Mowad-Nassar was granted 241 restricted stock units (RSUs) on 09/02/2025. The report shows the award as a non-derivative acquisition and lists 241 shares beneficially owned following the transaction, held in a direct form. The filing explains the RSUs vest on the first anniversary of the grant date. The Form 4 was signed on behalf of Ms. Mowad-Nassar by an attorney-in-fact on 09/03/2025. No price was reported for the grant and no other transactions or derivative positions are disclosed in this filing.
ResMed insider trades on 09/02/2025: Chief Financial Officer Brett Sandercock executed both an acquisition and a sale in ResMed common stock under a Rule 10b5-1 plan. He acquired 2,000 shares at $101.64 per share and sold 3,000 shares at $270.77 per share. Following these transactions his beneficial ownership is reported as 87,745 shares. The 2,000-share purchase reflects option-related activity: a grant of 2,000 options with an exercise price of $101.64 exercisable beginning 11/11/2019 and expiring 11/14/2025; options vest one-third per year. The Form 4 indicates the trades were made pursuant to a 10b5-1 trading plan adopted February 19, 2025.
ResMed Inc. director reports no beneficial ownership
ResMed Inc. director Nicole Mowad-Nassar filed an initial Form 3 ownership report in connection with an event dated 08/15/2025. The filing states that she serves as a Director of ResMed Inc. and that no securities are beneficially owned, with both the non-derivative and derivative ownership tables showing no holdings.
ResMed insider notice to sell 3,000 common shares via Fidelity on 09/02/2025. The filing reports an aggregate market value of $812,310 for the proposed sale and states the company has 146,414,839 shares outstanding. The shares to be sold were acquired through an options grant (11/14/2018) covering 2,000 shares and restricted stock vesting on 11/11/2022 (204 shares) and 11/18/2022 (796 shares). The filer also disclosed three prior sales over the past three months by Brett Sandercock totaling 7,883 shares for gross proceeds of $2,087,372.17. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.
Justin Leong, Chief Product Officer of ResMed Inc. (RMD), reported that 5,462 shares of company stock were acquired on 08/15/2025 upon the vesting of performance-based restricted stock units. These units were originally granted on 11/20/2024 and were certified as earned by the compensation committee when the performance metrics were met.
Following the transaction, Mr. Leong beneficially owns 27,180 shares. The reported acquisition shows a transaction code of A(1) with a reported price of $0, consistent with earned compensation rather than a market purchase.
Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), reported that 5,462 shares of ResMed common stock were issued to him on 08/15/2025 as the result of performance-based restricted stock units (RSUs) granted on 11/20/2024. The filing shows the shares were earned when the company's compensation committee certified that the performance metrics were met; the RSUs have a vesting schedule of one-third each anniversary of the grant.
Following this issuance, Mr. Sandercock beneficially owns 88,745 shares. The reported transaction lists a price of $0, reflecting the settlement of vested RSUs rather than an open-market purchase, and the Form 4 is signed and dated 08/19/2025.